Evidence map›Paper›PMID 42694666›Full record

ArticleFrontiers in immunology2026

Impact of IL-6 and ferritin dynamics on clinical outcomes after anti-CD19 CAR-T cell therapy in diffuse large B-cell lymphoma patients.

Ling Gao, Yanyan Mao, Cai Sun, Yize Li, Xing Xing, Yuqing Miao, Chunling Wang, Hongfeng Ge, Ziyuan Shen, Wei Sang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ling Gao *Department of Hematology, Jiangsu Province (Suqian) Hospital, Suqian, Jiangsu, China.
Yanyan Mao *Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Cai SunDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yize LiDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xing XingDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Yuqing MiaoDepartment of Hematology, Yancheng First People's Hospital, Yancheng, Jiangsu, China.
Chunling WangDepartment of Hematology, The First People's Hospital of Huai'an, Huai'an, Jiangsu, China.
Hongfeng GeDepartment of Hematology, Bozhou People's Hospital, Bozhou, Anhui, China.
Ziyuan ShenClinical Research Institute, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Wei SangDepartment of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Interleukin-6 (IL-6) and ferritin are routinely monitored during chimeric antigen receptor T-cell (CAR-T) therapy; however, their temporal dynamics and outcome-specific relevance remain inadequately characterized. This study aimed to evaluate the value of IL-6 and ferritin at multiple time points in patients with diffuse large B-cell lymphoma (DLBCL) receiving anti-CD19 CAR-T therapy. Methods: A total of 54 patients (median age 49.0 years; 64.8% male) were retrospectively analyzed. Post-infusion IL-6 and ferritin levels were measured on day 1, day 7, day 14, and the peak value was defined as the highest level within the first 14 days after infusion. Survival was evaluated using Cox proportional hazards regression, while logistic regression was used for binary outcomes, with Firth penalized regression performed as a sensitivity analysis. Spearman correlation was used to characterize relationships between IL-6, ferritin, and routine laboratory parameters. Results: CRS occurred in 68.5% of patients, and the objective response rate was 70.4%. IL-6 levels were significantly higher in patients with CRS at day 1 ( Conclusion: Serial IL-6 and ferritin measurements were associated with CRS-related inflammatory status. Day +7 IL-6 and Day +7 ferritin showed exploratory associations with mortality.

Indexed as

Antigens, CD19FerritinsImmunotherapy, AdoptiveInterleukin-6Lymphoma, Large B-Cell, DiffuseAdultAgedFemaleHumansMaleMiddle AgedReceptors, Chimeric AntigenRetrospective StudiesTreatment OutcomeAntigens, CD19FerritinsIL6 protein, humanInterleukin-6Receptors, Chimeric AntigenCAR-TDLBCLferritininterleukin-6prognosis

Identifiers

PMID42694666
PMCPMC13539416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.